Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

NCT07543380

RecruitingPhase 3

Sponsor: Pfizer

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: RSVpreF

Countries: Japan

The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adults with health condition(s) that can put them at an increased risk of severe RSV disease It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.

Eligibility overview

Sex: ALL

Age: 18 Years to 59 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key Inclusion Criteria:

• Underlying health condition(s) that can put the participant at an increased risk of severe RSV/complications including chronic lung , heart, kidney, liver, nervous system, blood, or metabolic diseases

Key Exclusion Criteria:

* Received any kind of RSV vaccine before participating in this study
* Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s)

Please refer to the study contact for further eligibility details.
Locations (5)
  • Tsuchiura, Ibaraki, Japan
  • Chuo-ku, Tokyo, Japan
  • Chuo-ku, Tokyo, Japan
  • Chuo-ku, Tokyo, Japan
  • Fukuoka, Japan